EFFECTS OF H2 BLOCKERS, PROTON PUMP INHIBITORS AND EZETIMIBE ON THYROXINE ABSORP

H2 阻滞剂、质子泵抑制剂和依泽替米贝对甲状腺素吸收的影响

• 批准号: 7606271
• 负责人: Elizabeth N. Pearce
• 金额: $ 3.65万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-01-03 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606271
• 关键词: Clinical; Computer Retrieval of Information on Scientific Projects Database; Daily; Dose; Funding; Grant; Histamine-2 Receptor Antagonist; Hour; Institution; Patients; Proton Pump Inhibitors; Pump; Replacement Therapy; Research; Research Personnel; Resources; Serum; Source; Testing; Thyroid Hormones; Thyroxine; United States National Institutes of Health; Week; absorption; experience; ezetimibe; healthy volunteer; inhibitor/antagonist; volunteer

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Thyroxine replacement therapy (LT4) is used to treat hypothyroid patients. We plan to examine the effects that histamine 2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) each have on LT4 absorpition. Also, in our clinical experience, ezetimibe may interfere with LT4 absorption. in our study, at baseline, healthy volunteers will be given a dose of LT4 and undergo successive lab tests over 8 hours to examine the rise of serum thyroid hormone levels. After a washout period of six to eight weeks, these same volunteers will be given either daily doses of an H2RA or a PPI for one week or a single dose of ezetimibe. A single LT4 dose will be administered again at the end of the week, followed by repeat drawing of serum thyroid hormone levels. We will compare thyroid hormones concentrations achieved following LT4 administration to the healthy volunteer at baseline versus after therapy with: a) week long course of an H2RA, b) week long course of a PPI or c) simultaneously administered dose of ezetimibe.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 甲状腺素替代疗法（LT4）用于治疗甲状腺功能减退患者。我们计划检查组胺 2 受体拮抗剂 (H2RA) 和质子泵抑制剂 (PPI) 对 LT4 吸收的影响。此外，根据我们的临床经验，依折麦布可能会干扰 LT4 吸收。在我们的研究中，在基线时，健康志愿者将接受一定剂量的 LT4，并在 8 小时内进行连续的实验室测试，以检查血清甲状腺激素水平的上升情况。经过六到八周的清除期后，这些志愿者将每天服用 H2RA 或 PPI，持续一周，或单剂量依折麦布。将在周末再次注射单剂 LT4，然后重复抽取血清甲状腺激素水平。我们将比较健康志愿者 LT4 给药后在基线时与治疗后达到的甲状腺激素浓度：a) 为期一周的 H2RA 疗程，b) 为期一周的 PPI 疗程或 c) 同时给予依折麦布剂量。